Physician profile
Yvette Lopez
NPI 1164291654
$5,053.80
in general payments reported to CMS, 2019-2025
21 companies · $3,304 in 2025
The $3,304 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,750 · 2025: $3,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,034 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,033.58 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $649.72 | 2024-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $565.86 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $487.12 | 2024-2025 | |
| Penumbra, INC. | $404.99 | 2025 | Ruby Coil, Indigo System |
| Amgen INC. | $352.39 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $309.39 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $296.49 | 2024 | Xarelto |
| Novo Nordisk INC | $262.81 | 2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $215.44 | 2024-2025 | Verquvo, Capvaxive |
| Tactile Systems Technology INC | $214.72 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Averitas Pharma INC. | $183.75 | 2025 | Qutenza |
| Endologix LLC | $179.20 | 2024-2025 | Torus Stent Graft System, Endocross Device |
| W. L. Gore & Associates, INC. | $141.60 | 2025 | Gore Viabahn Endoprosthesis With Heparin |
| Esperion Therapeutics, INC. | $139.18 | 2024 | Nexletol, Nexlizet |
| Boston Scientific Corporation | $137.75 | 2025 | Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.01 | 2024 | Farxiga |
| Becton, Dickinson and Company | $114.39 | 2024 | Lifestream |
| Lexicon Pharmaceuticals, INC. | $110.17 | 2024 | Inpefa |
| Madrigal Pharmaceuticals | $98.25 | 2025 | Rezdiffra |
| Pfizer INC. | $39.57 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $26.00 | 2025 | Lutonix Drug Coated Balloon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.